Pacific Biosciences of California(US:PACB) ZACKSยท2025-07-29 23:16Company Performance - Pacific Biosciences of California (PACB) closed at $1.54, reflecting a -6.1% change from the previous day, underperforming the S&P 500's daily loss of 0.3% [1] - Over the past month, PACB shares have increased by 32.26%, significantly outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The company's earnings report is scheduled for August 7, 2025, with projected EPS of -$0.18, indicating a 10.00% increase compared to the same quarter last year [2] - Revenue is estimated to be $36.46 million, reflecting a 1.26% increase from the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of -$0.64 per share and revenue of $155.44 million, representing changes of +22.89% and +0.92% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Pacific Biosciences indicate evolving short-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns PACB a rank of 2 (Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 158, placing it in the bottom 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]